Clovis Oncology Shares Up 3.8%; Gabelli Issued Earlier Note Highlighting Stock As The Top Biotech Pick For 2019 Given Tesaro Acquisition, 'CLVS will become the only standalone PARP, which we believe makes it the most likely takeout target in 2019'
Benzinga Newsdesk